A Phase II Study of Endostar (Recombinant Human Endostatin ®) With Cisplatin and Capecitabine (Xeloda) as 1st Line Treatment in the Advanced Gastric Cancer
Endostar, a recombinant human endostatin, has shown its antitumor ability in combination in
NSCLC and breast cancer. But to gastric cancer, few clinical data has been reported.
However, bevacizumab, an angiogenesis inhibitor was shown effective in combination with
chemotherapy in advanced gastric cancer in some phase II study. So in this study, we want
to explore whether endostar is also effective and safe in advanced gastric cancer. Response
predictive factor is expected to be identified.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
3 year
No
lin shen, MD
Principal Investigator
Peking University, School of oncology, Department of GI oncology
China: Food and Drug Administration
ENDOCX
NCT00842491
November 2008
December 2010
Name | Location |
---|